Biogen seeks FDA approval for Alzheimer’s drug; aims to be first to slow disease
Treatment with aducanumab reduced declines in memory, language, and activities of daily living performance, the drugmaker says.
Alzheimer’s Research
Study suggests that Alzheimer’s drugs could reverse diabetes damage
Failed Alzheimer’s drugs could be repurposed to target an enzyme that may lead to heart attack and stroke, say investigators.
Clinical Briefs for Monday, April 13
More than 2,200 COVID-19 deaths in nursing homes … Lack of data, testing puts residents at risk of coronavirus: provider survey … More evidence found that ultrasound can aid in delivering future Alzheimer’s treatments … FDA approves first generic albuterol inhaler to meet rising demand
Biogen not giving up on Alzheimer’s treatment with mixed past
After a bit of a bumpy ride in 2019, Biogen’s injectable treatment for early Alzheimer’s is set for a late-stage clinical trial.
Clinical Briefs for Tuesday, January 7
Nursing homes in 11 states may see reduction in transportation rates for portable X-ray suppliers … Many older adults use online reviews to choose doctor – with caution, poll finds … Nonconforming breast cancer treatment in elderly women may not worsen outcomes … Unorthodox Alzheimer’s researcher Robert Moir dies at 58
Do you want to know that you’ll develop Alzheimer’s? For many, the answer is yes
Most adults want to know that they have Alzheimer’s disease before symptoms appear, finds a UK survey. And 75% are willing to be tested.
Clinical Briefs for Friday, October 11
Research sheds new light on how brain forms, recalls memories … FDA approves Dexcom G6 Pro continuous glucose monitor … Acute respiratory viral illness surveillance possible in long-term care: study … Targeting immune cells has potential as Alzheimer’s therapy
Clinical Briefs for Tuesday, October 8
Skin test designed to detect early Parkinson’s … Oral anticoagulant slows Alzheimer’s progression in mice … Oral capsule delivers injection-only drugs such as insulin
Clinical Briefs for Monday, October 7
New publication spotlights care for dementia-related psychosis … Drug has potential to treat heart attacks …. Statins may lower risk of post-stroke cognitive impairment … NIA to spend $73M to ‘reinvigorate’ Alzheimer’s research
Alzheimer’s cure would mean $16B in lost revenues for assisted living
A cure for Alzheimer’s disease would be a “medical miracle” but would result in a loss of $16.3 billion in assisted living annual revenues.
